1. Home
  2. CAC vs ORIC Comparison

CAC vs ORIC Comparison

Compare CAC & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAC
  • ORIC
  • Stock Information
  • Founded
  • CAC 1875
  • ORIC 2014
  • Country
  • CAC United States
  • ORIC United States
  • Employees
  • CAC N/A
  • ORIC N/A
  • Industry
  • CAC Major Banks
  • ORIC Biotechnology: Pharmaceutical Preparations
  • Sector
  • CAC Finance
  • ORIC Health Care
  • Exchange
  • CAC Nasdaq
  • ORIC Nasdaq
  • Market Cap
  • CAC N/A
  • ORIC 362.9M
  • IPO Year
  • CAC 1997
  • ORIC 2020
  • Fundamental
  • Price
  • CAC $43.03
  • ORIC $10.65
  • Analyst Decision
  • CAC Hold
  • ORIC Strong Buy
  • Analyst Count
  • CAC 3
  • ORIC 8
  • Target Price
  • CAC $47.33
  • ORIC $18.83
  • AVG Volume (30 Days)
  • CAC 55.2K
  • ORIC 1.0M
  • Earning Date
  • CAC 07-29-2025
  • ORIC 08-11-2025
  • Dividend Yield
  • CAC 3.89%
  • ORIC N/A
  • EPS Growth
  • CAC 2.54
  • ORIC N/A
  • EPS
  • CAC 3.09
  • ORIC N/A
  • Revenue
  • CAC $184,324,000.00
  • ORIC N/A
  • Revenue This Year
  • CAC $40.83
  • ORIC N/A
  • Revenue Next Year
  • CAC $5.29
  • ORIC N/A
  • P/E Ratio
  • CAC $14.00
  • ORIC N/A
  • Revenue Growth
  • CAC 13.26
  • ORIC N/A
  • 52 Week Low
  • CAC $31.79
  • ORIC $3.90
  • 52 Week High
  • CAC $50.07
  • ORIC $14.67
  • Technical
  • Relative Strength Index (RSI)
  • CAC 68.35
  • ORIC 68.45
  • Support Level
  • CAC $38.11
  • ORIC $9.80
  • Resistance Level
  • CAC $40.92
  • ORIC $11.19
  • Average True Range (ATR)
  • CAC 0.99
  • ORIC 0.60
  • MACD
  • CAC 0.44
  • ORIC -0.05
  • Stochastic Oscillator
  • CAC 88.50
  • ORIC 76.92

About ORIC Oric Pharmaceuticals Inc.

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Share on Social Networks: